Amgenvs.Gilead Sciences
AMGN vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.3× larger than Gilead Sciences by market cap; year to date, Amgen leads (+35.6% vs +19.6%).
Side by side
| AMGN | GILD | |
|---|---|---|
| Market cap | $226B | $170B |
| Price | $442.24 | $148.77 |
| Today | −0.4% | +1.4% |
| Return YTD | +35.6% | +19.6% |
| Return 1Y | +51.1% | +27.9% |
| P/E | 25.8 | — |
| P/S | 5.9 | 5.6 |
| P/B | 19.3 | 14.4 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More AMGN & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.
See where AMGN and GILD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →